Revenue Update on Simulations Plus(NASDAQ:SLP)

Simulations Plus(NASDAQ:SLP) announced the earnings results for Fiscal Year 2016 and Q3. The results came in during After-hours on Jul 14, 2016. Company reported revenue of $6.01M. Analysts estimated a revenue of $6.57M. Earnings per share were $0.11. Analysts had estimated an EPS of $0.12.

Simulations Plus (SLP) made into the market gainers list on Mondays trading session with the shares advancing 0.38% or 0.03 points. Due to strong positive momentum, the stock ended at $7.84, which is also near the day’s high of $7.93. The stock began the session at $7.89 and the volume stood at 22,902 shares. The 52-week high of the shares is $11.8899 and the 52 week low is $6.08. The company has a current market capitalization of $134 M and it has 1,70,51,964 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Feb 2, 2016, Walter S Woltosz (CEO) sold 58,181 shares at $11.27 per share price.

Simulations Plus Inc. (Simulations Plus) develops and produces software for use in pharmaceutical research and for education and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption Distribution Metabolism Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200000 compounds per hour. MedChem Designer includes a small set of ADMET Predictor property predictions allowing the chemist to modify molecular structures. MedChem Studio is a tool for medicinal and computational chemists for both data mining and for designing new drug-like molecules. DDDPlus simulates in-vitro laboratory experiments used to measure the rate of dissolution of the drug. GastroPlus simulates the absorption pharmacokinetics and pharmacodynamics of drugs.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *